首页期刊介绍编委会投稿须知电子期刊广告合作联系我们下载专区留言板

 《中国期刊网》《中国学术期刊(光盘版)全文收录》《中国学术期刊综合评价数据库》来源期刊 “万方数据-数字化期刊群”全文上网《中国核心期刊(遴选数据库)收录》《中文科技期刊数据库》来源期刊《龙源期刊网》合作期刊    友情提醒:我刊未委托任何单位、网站或个人代理征稿,以免上当受骗。

位置:首页 >> 电子期刊 >> 正文
抗乙型肝炎病毒免疫治疗研究新进展
作者:韦武均1 2 邓益斌1 2▲ 
单位:(1.右江民族医学院附属医院医学检验科 2.广西肝胆疾病临床医学研究中心 百色 533000) 
关键词:乙型肝炎病毒 共价闭合环状DNA 免疫治疗 
分类号:
出版年,卷(期):页码:2019,47(8):561-565
摘要:

抗乙型肝炎病毒(HBV)免疫治疗主要通过介导激活免疫细胞及释放细胞因子发挥免疫调控作用,增强宿主产生有效的先天性和适应性免疫应答,从而有效抑制HBV复制与转录,实现长期稳定的控制。该综述总结抗HBV免疫治疗的几种策略,以期找到清除HBV共价闭合环状DNA治疗新方法或药物,为HBV抗病毒治疗提供参考。

Immunotherapy mostly plays an role of immune regulatory in anti-hepatitis B virus(HBV) by mediating activation of immune cells and releasing cytokines,which produces effective innate and adaptive immune responses through enhancing the host,thus effectively inhibiting HBV replication and transcription,and achieving long-term stability control.This article reviews several strategies for anti-HBV immunotherapy in order to find new methods or drugs for clearing covalently closed circular DNA of HBV,providing reference for HBV antiviral therapy.

基金项目:
国家自然科学基金(81460123);广西自然科学基金(2018GXNSFAA281187);广西壮族自治区硕士研究 创新项目(YCSW2018215);百色市科学研究与技术开发计划项目(20182512)
作者简介:
参考文献:

[1] Stanaway JD,Flaxman AD,Naghavi M,et al.The global burden of viral hepatitis from 1990 to 2013:findings from the Global Burden of Disease Study 2013[J].Lancet,2016,388(10049):1081-1088.
[2]  Trepo C,Chan HL,Lok A.Hepatitis B virus infection[J].Lancet,2014,384(9959):2053-2063.
[3]  王芳芳,张国范,郭春霞,等.长期口服恩替卡韦治疗的慢性乙型肝炎患者换用α干扰素治疗临床疗效随访研究[J].实用肝脏病杂志,2018,21(5):721-724.
[4]  Garcia-Sastre A,Biron CA.Type 1 interferons and the virus-host relationship:a lesson in detente [J].Science,2006,312(5775):879-882.
[5]  Korkmaz P,Usluer G,Ozgunes I,et al.Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients[J].North Clin Istanb,2014,1(1):26-32.
[6]  Kang L,Pan J,Wu J,et al.Anti-HBV Drugs:Progress,Unmet Needs,and New Hope[J].Viruses,2015,7(9):4960-4977.
[7]  马文心.中医中药治乙肝的临床效果观察[J].大家健康(学术版),2014,8(21):43-44.
[8]  Xia J,Inagaki Y,Song P,et al.Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus[J].Biosci Trends,2016,10(5):327-336.
[9]  Fang X,Liu L,Dong J,et al.A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis[J].J Gastroenterol Hepatol,2018,33(4):774-780.
[10] Qu M,Yuan X,Liu D,et al.Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Immune-Mediated Liver Injury and Compromise Virus Control During Acute Hepatitis B Virus Infection in Mice[J].Stem Cells Dev,2017,26(11):818-827.
[11] 于双杰,陈黎明,吕飒,等.人脐带间充质干细胞治疗失代偿性乙型肝炎肝硬化的安全性与疗效[J].中华肝脏病杂志,2016,24(1):51-55.
[12] Swiecki M,Colonna M.The multifaceted biology of plasmacytoid dendritic cells[J].Nat Rev Immunol,2015,15(8):471-485.
[13] Belloni L,Allweiss L,Guerrieri F,et al.IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J].J Clin Invest,2012,122(2):529-537.
[14] van der Aa E,van Montfoort N,Woltman AM.BDCA3(+)CLEC9A(+) human dendritic cell function and development[J].Semin Cell Dev Biol,2015,41:39-48.
[15] Yoshio S,Kanto T.Host-virus interactions in hepatitis B and hepatitis C infection[J].J Gastroenterol,2016,51(5):409-420.
[16] Chen M,Li YG,Zhang DZ,et al.Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B:a clinical study[J].World J Gastroenterol,2005,11(12):1806-1808.
[17] Zhuang L,Tian J,Zhang X,et al.Lnc-DC regulates cellular turnover and the HBV-induced immune response by TLR9/STAT3 signaling in dendritic cells[J].Cell Mol Biol Lett,2018,23:43.
[18] 谢丽平,林涛发,朱玲玲,等.慢性乙型肝炎患者在HBV不同抗原负载下树突状细胞功能的变化[J].肝脏,2017,22(7):594-596.
[19] Han Q,Zhang C,Zhang J,et al.The role of innate immunity in HBV infection[J].Semin Immunopathol,2013,35(1):23-38.
[20] Zheng M,Sun H,Tian Z.Natural killer cells in liver diseases[J].Front Med,2018,12(3):269-279.
[21] 胡辛,胡春松,黄保军.自然杀伤细胞分泌干扰素γ促进乙肝病毒的清除[J].安徽医科大学学报,2017,52(2):215-220.
[22] Zheng M,Sun R,Wei H,et al.NK Cells Help Induce Anti-Hepatitis B Virus CD8+T Cell Immunity in Mice[J].J Immunol,2016,196(10):4122-4131.
[23] Tong S,Liu G,Li M,et al.Natural killer cell activation contributes to hepatitis B viral control in a mouse model[J].Sci Rep,2017,7(1):314.
[24] Wang Y,Wang W,Shen C,et al.NKG2D modulates aggravation of liver inflammation by activating NK cells in HBV infection[J].Sci Rep,2017,7(1):88.
[25] Yoshioka T,Tatsumi T,Miyagi T,et al.Frequency and role of NKp46 and NKG2A in hepatitis B virus infection[J].PLoS One,2017,12(3):e174103.
[26] Park JJ,Wong DK,Wahed AS,et al.Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B[J].Gastroenterology,2016,150(3):684-695.
[27] Kah J,Koh S,Volz T,et al.Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection[J].J Clin Invest,2017,127(8):3177-3188.
[28] Shao X,Ma J,Jia S,et al.Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection[J].Front Cell Infect Microbiol,2017,7:472.
[29] Fisicaro P,Barili V,Montanini B,et al.Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B[J].Nat Med,2017,23(3):327-336.
[30] Xia Y,Stadler D,Lucifora J,et al.Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells Reduce the HBV Persistence Form,cccDNA,Without Cytolysis[J].Gastroenterology,2016,150(1):194-205.
[31] Koh S,Shimasaki N,Bertoletti A.Redirecting T Cell Specificity Using T Cell Receptor Messenger RNA Electroporation[J].Methods Mol Biol,2016,1428:285-296.
[32] Kah J,Koh S,Volz T,et al.Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection[J].J Clin Invest,2017,127(8):3177-3188.
[33] Zhang E,Lu M.Toll-like receptor(TLR)-mediated innate immune responses in the control of hepatitis B virus(HBV) infection[J].Med Microbiol Immunol,2015,204(1):11-20.
[34] Das D,Sarkar N,Sengupta I,et al.Anti-viral role of toll like receptor 4 in hepatitis B virus infection:An in vitro study[J].World J Gastroenterol,2016,22(47):10341-10352.
[35] Zhang X,Ma Z,Liu H,et al.Role of Toll-like receptor 2 in the immune response against hepadnaviral infection[J].J Hepatol,2012,57(3):522-528.
[36] Isogawa M,Robek MD,Furuichi Y,et al.Toll-like receptor signaling inhibits hepatitis B virus replication in vivo[J].J Virol,2005,79(11):7269-7272.
[37] Mcgowan D,Herschke F,Pauwels F,et al.Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus[J].J Med Chem,2016,59(17):7936-7949.
[38] Alsaab HO,Sau S,Alzhrani R,et al.PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy:Mechanism,Combinations,and Clinical Outcome[J].Front Pharmacol,2017,8:561.
[39] Tang ZS,Hao YH,Zhang EJ,et al.CD28 family of receptors on T cells in chronic HBV infection:Expression characteristics,clinical significance and correlations with PD-1 blockade[J].Mol Med Rep,2016,14(2):1107-1116.
[40] Balsitis S,Gali V,Mason PJ,et al.Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection[J].PLoS One,2018,13(2):e190058.
[41] Qiu SJ,Zhou ZG,Shen F,et al.A multicenter,randomized,observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection- first announcement of the protocol[J].Expert Opin Biol Ther,2015,15 Suppl 1:S133-S137.
[42] 李春柱,曹世敏,胡丽华.胸腺肽α-1联合恩替卡韦对慢性乙型肝炎患者肝功能及血清HBeAg转阴率的影响[J].中国地方病防治杂志,2018,33(5):577-578.
[43] Naylor PH,Mutchnick MG.Immunotherapy for hepatitis B in the direct acting antiviral era:Reevaluating the thymosin alpha1 efficacy trials in the light of a combination therapy approach[J].J Viral Hepat,2018,25(1):4-9.
[44] Li J,Bao M,Ge J,et al.Research progress of therapeutic vaccines for treating chronic hepatitis B[J].Hum Vaccin Immunother,2017,13(5):986-997.
[45] King TH,Kemmler CB,Guo Z,et al.A whole recombinant yeast-based therapeutic vaccine elicits HBV X,S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance[J].PLoS One,2014,9(7):e101904.
[46] Zhu D,Liu L,Yang D,et al.Clearing Persistent Extracellular Antigen of Hepatitis B Virus:An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination[J].J Immunol,2016,196(7):3079-3087.

 

服务与反馈:
文章下载】【加入收藏

 右江民族医学院附属医院《右江医学》编辑部版权所有 CopyRight:www.yjyx.org All Rights Reserved.
本网站所刊登的各种新闻﹑信息、材料和各种稿件,版权均归本编辑部所有,未经协议授权,禁止转载、禁止下载使用。
本网站由右江民族医学院附属医院《右江医学》编辑部及博科思网络技术(北京)有限公司共同维护
编辑部电话/传真:0776-2825575;网站技术支持电话:010-68713668-9088
地址:广西百色市中山二路18号,邮编:533000
备案号:桂ICP备06012708号-3      公安局备案号:45100202000267号